Table 3.

Univariate and multivariate Cox proportional hazard regression in EBV⁺ DLBCL-NOS (n = 70)

Variable	Univariate analysis				Multivariate analysis
	PFS		OS		PFS		OS
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
ECOG-PS ≥ 2	16.26 (4.32, 61.28)	<.001	15.91 (3.75, 67.61)	<.001	—		—
Age >50 y	10.74 (2.72, 42.43)	< .001	9.93 (2.34, 41.09)	.002	14.01 (2.34, 83.97)	.004	12.41 (1.65, 93.54)	.014
HLH	7.35 (3.11, 17.37)	< .001	8.31 (3.44, 20.06)	<.001	5.78 (2.35, 14.23)	< .001	6.09 (2.42, 15.30)	< .001
aaIPI ≥ 2	6.68 (1.57, 28.46)	.010	12.22 (1.64, 91.18)	.015	3.03 (0.68, 13.47)	.14	5.76 (0.75, 44.53)	.093
B symptoms	5.38 (1.28, 22.68)	.022	4.78 (1.13, 20.27)	.034	—		—
Clinical stage III-IV	3.45 (1.04, 11.44)	.043	4.68 (1.11, 19.84)	.036	—		—
Extranodal disease	2.79 (1.30, 5.99)	.008	2.74 (1.23, 6.13)	.014	—		—
Lymphopenia	2.47 (0.83, 7.36)	.103	3.18 (0.92, 10.90)	.066	—		—
LDH elevated	2.07 (0.71, 6.06)	.185	2.69 (0.79, 9.11)	.112	—		—
Latency type III	2.09 (0.74, 5.89)	.160	2.13 (0.71, 6.39)	.180	—		—
Female	0.95 (0.47, 1.94)	.900	1.14 (0.55, 2.38)	.720	—		—
PD-L1 H-score > 150	0.68 (0.27, 1.73)	.420	0.60 (0.23, 1.56)	.290	—		—
Polymorphic	0.60 (0.29, 1.25)	.170	0.62 (0.29, 1.34)	.220	—		—